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Meta-analysis identiﬁes ﬁve novel loci associated
with endometriosis highlighting key genes involved
in hormone metabolism
Yadav Sapkota1,2, Valgerdur Steinthorsdottir3, Andrew P. Morris4,5, Amelie Fassbender6,7, Nilufer Rahmioglu5,
Immaculata De Vivo8,9, Julie E. Buring8,10, Futao Zhang11, Todd L. Edwards12, Sarah Jones13, Dorien O6,7, Danie¨lle Peterse6,7,
Kathryn M. Rexrode8,10, Paul M. Ridker8,10, Andrew J. Schork14,15, Stuart MacGregor1, Nicholas G. Martin1,
Christian M. Becker16, Sosuke Adachi17, Kosuke Yoshihara17, Takayuki Enomoto17, Atsushi Takahashi18, Yoichiro Kamatani18,
Koichi Matsuda19, Michiaki Kubo18, Gudmar Thorleifsson3, Reynir T. Geirsson20,21, Unnur Thorsteinsdottir3,21,
Leanne M. Wallace1,11, iPSYCH-SSI-Broad Groupw, Jian Yang11, Digna R. Velez Edwards22, Mette Nyegaard23,24,
Siew-Kee Low18,*, Krina T. Zondervan5,16,*, Stacey A. Missmer8,9,*, Thomas D’Hooghe6,7,25,*, Grant W. Montgomery1,11,*,
Daniel I. Chasman8,10,*, Kari Stefansson3,21,*, Joyce Y. Tung26,* & Dale R. Nyholt1,27,*
Endometriosis is a heritable hormone-dependent gynecological disorder, associated with severe pelvic
pain and reduced fertility; however, its molecular mechanisms remain largely unknown. Here we perform
a meta-analysis of 11 genome-wide association case-control data sets, totalling 17,045 endometriosis
cases and 191,596 controls. In addition to replicating previously reported loci, we identify ﬁve novel loci
signiﬁcantly associated with endometriosis risk (Po5 108), implicating genes involved in sex steroid
hormone pathways (FN1, CCDC170, ESR1, SYNE1 and FSHB). Conditional analysis identiﬁed ﬁve secondary
association signals, including two at the ESR1 locus, resulting in 19 independent single nucleotide
polymorphisms (SNPs) robustly associated with endometriosis, which together explain up to 5.19% of
variance in endometriosis. These results highlight novel variants in or near speciﬁc genes with important
roles in sex steroid hormone signalling and function, and offer unique opportunities for more targeted
functional research efforts.
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E
ndometriosis is a common gynecological disorder that
affects 6–10% of women of reproductive age1 and 20–50%
of women with infertility2. The disease is associated with
pelvic pain and is primarily characterized by the presence of
endometrium-like tissue outside the uterus. The etiology of
endometriosis is complex, involving multiple genetic and
environmental risk factors. The condition has an estimated
total heritability of 0.47–0.51 based on twin studies1,3, and a
common SNP-based heritability of 0.26 (ref. 4).
Genome-wide association (GWA) studies have identiﬁed
11 independent single-nucleotide polymorphisms (SNPs) for
endometriosis. These SNPs include rs10965235 in CDKN2BAS on
chromosome 9p21.3 identiﬁed in a Japanese ancestry GWA
study5; rs1519761 on 2q23.3 identiﬁed in a US GWA study of
European-ancestry women6; seven loci (rs7521902 near WNT4
on 1p36.12, rs13391619 in GREB1 on 2p25.1, rs4141819 on 2p14,
rs7739264 near ID4 on 6p22.3, rs12700667 on 7p15.2, rs1537377
near CDKN2B-AS1 (independent of rs10965235) on 9p21.3 and
rs10859871 near VEZT on 12q22) identiﬁed in a European-
ancestry GWA study7 and from a meta-analysis of European and
Japanese ancestry GWA data8; and most recently rs17773813
near KDR on 4q12 and rs519664 in TTC39B on 9p22 in an
Icelandic GWA study9. We also recently conﬁrmed the suggested
association of the IL1A gene locus on 2q13, by identifying
genome-wide signiﬁcant association between rs6542095 and
endometriosis10,11. Thus, bringing the total to 12 independent
SNPs associated with endometriosis at the genome-wide
signiﬁcance level, of which all but one (rs10965235 in
CDKN2BAS on 9p21.3, identiﬁed in the Japanese GWA study5)
are polymorphic in populations of European ancestry. Of the 11
European SNP risk loci, eight SNPs have been replicated and
robustly implicated as susceptibility loci for endometriosis10,12,
the exceptions being rs1519761 (2q23.3), rs17773813 (4q12) and
rs519664 (TTC39B) that are yet to be examined in an
independent study.
To gain a better understanding of the genetic architecture of
endometriosis, we sought to substantially expand upon the
existing GWA data for endometriosis. Including 11 individual
case-control data sets of European and Japanese ancestries (ten
imputed using a recent 1000 Genomes Project reference panel
and one directly genotyped), the current meta-analysis represents
an approximate ﬁve-fold increase in the effective sample size13 in
comparison to the previously largest multi-ethnic GWA meta-
analysis of 4,604 endometriosis cases and 9,393 controls from
Australia, United Kingdom and Japan8. In addition to replicating
9 of the 11 previously reported European risk loci, this GWA
meta-analysis identiﬁed 5 novel loci signiﬁcantly associated with
endometriosis risk (Po5 10 8), implicating genes involved in
sex steroid hormone pathways (FN1, CCDC170, ESR1, SYNE1
and FSHB). Conditional analyses identiﬁed ﬁve novel secondary
association signals at these implicated loci, including two at the
ESR1 locus, resulting in a total of 19 independent SNPs robustly
associated with endometriosis, which together explain up to
5.19% of variance in endometriosis.
Results
Study overview. This meta-analysis combined GWA data from
11 individual GWA case–control data sets, totalling 17,045
endometriosis cases and 191,858 controls of European and
Japanese ancestries from Australia, Iceland, Belgium, the UK,
the USA, Denmark and Japan. Individuals in the study are pre-
dominantly Europeans representing B93% of the total effective
sample size (cases and controls), with the remaining B7% being
of Japanese descent. A brief summary of the 11 individual GWA
case–control data sets is provided in Supplementary Data 1. Seven
GWA data sets (QIMRHCS, OX, BBJ, deCODE, Adachi-6 and
Adachi-500K) have been published previously5,8–10,14,15 and the
remaining four are unpublished. Because individuals in the
Adachi data set were genotyped using two different platforms
(Affymetrix 500K and 6.0), they were processed and analysed as
separate GWA data sets. Details of individual data sets are
provided in the Supplementary Information. All cases in the
QIMRHCS, OX, deCODE and LEUVEN studies have surgically
conﬁrmed endometriosis and disease stage from surgical records
using the revised American Fertility Society (rAFS) classiﬁcation
system16; women were grouped into Grade A (rAFS I or II disease
or some ovarian disease with a few adhesions), Grade B (rAFS III
or IV disease) or unknown stage as described previously7.
Diagnosis of endometriosis in other studies is based on
self-reports or a combination of surgical records and self-report
(see Supplementary Information for more details).
Each GWA case–control data set followed similar quality
control procedures and was imputed separately using the same
1000 Genomes Project reference panel (March 2012 Release),
with the exception being the 23andMe and deCODE studies that
were imputed using the 1000 Genomes Project October 2010
haplotypes and whole genome sequence data (B30 million
sequence variants) of 8,453 Icelanders, respectively. The Adachi-6
data set consisted of only observed genotype data because
individual-level genotypes were not available to carry out
imputation. Genotypes (observed or imputed) in individual
GWA case–control data sets were analysed and processed using
similar approaches (see Methods section).
Primary GWA meta-analysis of all 17,045 endometriosis cases
versus 191,858 controls, for the 6,979,035 SNPs that passed
quality control in at least 50% (6 or more) of the participating
studies, was performed using a ﬁxed-effect model. SNPs
with Po0.05 in the primary GWA meta-analysis were further
analysed after excluding cases with minimal or mild (Grade A)
endometriosis (rAFS I or II disease) from the QIMRHCS,
deCODE, LEUVEN and OX cohorts. A total of 391 SNPs reached
conventional genome-wide signiﬁcance (Po5 10 8) and their
association summary results are provided in Supplementary
Data 2. SNPs showing suggestive association in the ﬁxed-effect
model and with evidence of heterogeneity (Pheto0.05) were also
analysed using the Han Eskin random-effects model (RE2)17. The
RE2 model is similar to the traditional RE approach except it
relaxes the conservative assumption in hypothesis testing and
assumes no heterogeneity under the null hypothesis of no
association. As such, it offers greater power under heterogeneity
as compared with the conventional random-effects model.
The genomic inﬂation factor (l) for the GWA meta-analysis
was 1.12. Quantile–quantile (Q–Q) plots for the ﬁxed-effect
GWA meta-analysis and 11 individual GWA case-control data
sets are provided in Supplementary Figs 1–12.
Risk loci associated with endometriosis. Of the 11 previously
reported European SNP risk loci, nine reached genome-wide
signiﬁcance (Po5 10 8) in the present study (Fig. 1 and
Table 1); we did not conﬁrm associations at 2q23.3 and 9p22. The
Q-Q plot for the ﬁxed-effect GWA meta-analysis including all
endometriosis cases (‘All’) after excluding the nine loci (the most
signiﬁcant (‘index’) SNPs and 1Mb ﬂanking region) is provided
in Supplementary Fig. 13. SNP associations at loci on 1p36.12,
7p15.2 and 9p21.3 remained genome-wide signiﬁcant when sec-
ondary meta-analysis (‘Grade B’) was performed after excluding
cases with known minimal or mild (Grade A) endometriosis
(rAFS I or II disease) (Table 1). Furthermore, all nine previously
reported loci produced larger effects (odds ratios (ORs)) in Grade
B analysis compared to the analysis of all cases—an observation
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consistent with previous reports of greater genetic loading in
moderate-to-severe endometriosis. Regional association plots of
the nine previously reported loci based on the ﬁxed-effect meta-
analysis results including all and Grade B endometriosis cases are
provided in Supplementary Figs 14–22.
In addition to robustly implicating nine previously identiﬁed
endometriosis SNP loci, the meta-analysis identiﬁed ﬁve new
genomic regions harbouring risk loci for endometriosis (Fig. 1
and Table 1). In the ‘All’ ﬁxed-effect meta-analysis, we observed
genome-wide signiﬁcant evidence for risk loci in CCDC170 on
6q25.1 (rs1971256: OR (95% conﬁdence interval (CI))¼ 1.09
(1.06–1.13); Pall¼ 3.74 10 8), in SYNE1 on 6q25.1 (rs71575922:
OR (95% CI)¼ 1.11 (1.07–1.15); Pall¼ 2.02 10 8) and near
FSHB on 11p14.1 (rs74485684: OR (95% CI)¼ 1.11 (1.07–1.15);
Pall¼ 2.00 10 8). The ‘Grade B’ ﬁxed-effect meta-analysis
implicated rs1250241 in FN1 on 2q35 (OR (95% CI)¼ 1.23
(1.15–1.30); PGrade B¼ 2.99 10 9) and rs74491657 on 7p12.3
(OR (95% CI)¼ 1.46 (1.28–1.59); PGrade B¼ 2.24 10 8) as
genome-wide signiﬁcantly associated with endometriosis risk
(Table 1). Regional association plots of loci on 6q25.1 (CCDC170
and SYNE1) and 11p14.1 (FSHB) based on ﬁxed-effect meta-
analysis results including all cases, and of loci on 2q35 and 7p12.3
based on results from ﬁxed-effect meta-analysis for Grade B cases
are provided in Fig. 2. Associations at the 6q25.1 CCDC170 and
SYNE1 loci remained genome-wide signiﬁcant in the ‘Grade B’
analysis, with larger effects (ORs) for the risk allele in comparison
to those based on analysis of all endometriosis cases (Table 1).
Regional association plots of the ﬁve newly identiﬁed loci
based on ﬁxed-effect meta-analysis including all and Grade B
endometriosis cases are provided in Fig. 2 and Supplementary
Fig. 23. Forest plots of risk allele effects (ORs) for the index SNPs
at 14 loci in the individual GWA case-control data sets, and for
the ‘All’ and ‘Grade B’ ﬁxed-effect meta-analyses are given in
Fig. 3 and Supplementary Figs 24–33.
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Figure 1 | Manhattan plot for genome-wide associations with endometriosis. Data are based on GWA meta-analysis of all endometriosis cases. The
horizontal axis shows the chromosomal position, and the vertical axis shows the signiﬁcance of tested markers combined in a ﬁxed-effects meta-analysis.
Markers that reached genome-wide signiﬁcance (Po5 108) are highlighted.
Table 1 | Summary of the GWA meta-analysis results for 14 genome-wide signiﬁcant loci.
Chr SNP Position (bp) RA OA Meta-analysis (All) Meta-analysis (Grade B) Associated
gene/cytoband
RAFEUR RAFJPT OR (95% CI) P value OR (95% CI) P value
Previously reported loci
1 rs12037376 22462111 A G 0.17 0.58 1.16 (1.12–1.19) 8.87 10 17 1.28 (1.18–1.36) 2.69 109 WNT4/1p36.12
2 rs11674184 11721535 T G 0.61 0.54 1.13 (1.10–1.15) 2.67 10 17 1.18 (1.10–1.24) 1.94 106 GREB1/2p25.1
2 rs6546324 67856490 A C 0.31 0.21 1.08 (1.05–1.11) 3.01 10 8 1.19 (1.11–1.26) 3.71 10 7 ETAA1/2p14
2 rs10167914 113563361 G A 0.30 0.75 1.12 (1.08–1.15) 1.10 10 9 1.15 (1.07–1.21) 7.59 10 5 IL1A/2q13
4 rs1903068 56008477 A G 0.68 0.88 1.11 (1.07–1.13) 1.04 10 11 1.33 (1.24–1.40) 2.58 10 15 KDR/4q12
6 rs760794 19790560 T C 0.43 0.71 1.09 (1.06–1.12) 1.79 10 10 1.17 (1.10–1.24) 8.74 10 7 ID4/6p22.3
7 rs12700667 25901639 A G 0.74 0.20 1.10 (1.07–1.13) 9.08 10 10 1.28 (1.19–1.36) 6.69 10 11 7p15.2
9 rs1537377 22169700 C T 0.40 0.39 1.09 (1.06–1.12) 1.33 10 10 1.21 (1.13–1.27) 6.31 109 CDKN2B-AS1/9p21.3
12 rs4762326 95668951 T C 0.47 0.48 1.08 (1.05–1.11) 2.20 10 9 1.15 (1.08–1.21) 1.08 10 5 VEZT/12q22
Novel loci
2 rs1250241 216295312 T A 0.29 0.06 1.06 (1.03–1.09) 6.20 10 5 1.23 (1.15–1.30) 2.99 109 FN1/2q35
6 rs1971256 151816011 C T 0.20 0.35 1.09 (1.06–1.13) 3.74 10 8 1.28 (1.19–1.36) 1.50 10 10 CCDC170/6q25.1
6 rs71575922 152554014 G C 0.16 — 1.11 (1.07–1.15) 2.02 10 8 1.35 (1.24–1.43) 2.87 10 12 SYNE1/6q25.1
7 rs74491657 46947633 G A 0.91 0.78 1.08 (1.03–1.13) 1.23 10 3 1.46 (1.28–1.59) 2.24 108 7p12.3
11 rs74485684 30242287 T C 0.84 0.98 1.11 (1.07–1.15) 2.00 10 8 1.26 (1.15–1.35) 7.77 10 7 FSHB/11p14.1
Chr, Chromosome; SNP, single-nucleotide polymorphism; Genomic position is shown relative to GRCh37 (hg19); GWA, genome-wide association; RA, risk allele; OA, other allele; OR, odds ratio with
respect to RA; CI, conﬁdence interval; RAFEUR, average risk allele frequency in European samples; RAFJPT, average risk allele frequency in Japanese samples.
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Figure 2 | LocusZoom plots of ﬁve genome-wide signiﬁcant endometriosis loci. Association with endometriosis is expressed as  log10(P value) for ﬁve
new genome-wide signiﬁcant loci: FN1 2q35 (2a), CCDC170 on 6q25.1 (2b), SYNE1 on 6q25.1 (2c), 7p12.3 (2d), and near FSHB on 11p14.1 (2e). Results
for 2q35 and 7p12.3 are based on analysis including only moderate-to-severe (’Grade B’) endometriosis cases. SNPs are shown as circles, diamonds or
squares (ﬁlled or unﬁlled), with the top SNP represented by purple colour. All other SNPs are colour coded according to the strength of LD with the top SNP
(as measured by r2 in the European 1000 Genomes data).
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Distinct association signals at endometriosis risk loci. To
identify distinct secondary association signals at the 14 loci, we
used the genome-wide complex trait analysis (GCTA) software18
to perform approximate conditional analysis based on summary
statistics from meta-analysis including all endometriosis cases.
For the FN1 2q35 and 7p12.3 loci, we used summary statistics
from meta-analysis including Grade B endometriosis cases.
We conservatively deﬁned a locus as the chromosomal region
500 kb up- and down-stream of the index SNP at the locus.
We estimated the effective number of independent SNPs to be
11,631 across all 14 regions. We therefore used a region-wide
Bonferroni adjusted signiﬁcant threshold of Po4.3 10 6 to
declare a secondary association signal if a SNP achieved
this threshold after conditioning on the index SNP at each
locus. GCTA identiﬁed ﬁve secondary signals including one
(rs77294520 near GREB1) on 2p25.1; two (rs2206949 in ESR1 and
rs17803970 in SYNE1) on 6q25.1, and two (rs10757272 in
CDKN2B-AS1 and rs1448792) on 9p21.3 (Table 2). Of these,
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Figure 3 | Forest plots showing risk allele effects for ﬁve endometriosis loci. Risk allele effects for the ﬁve new genome-wide signiﬁcant loci in the
individual case-control data sets and GWA meta-analysis: FN1 2q35 (3a), CCDC170 on 6q25.1 (3b), SYNE1 on 6q25.1 (3c), 7p12.3 (3d), and near FSHB on
11p14.1 (3e). Results for 2q35 and 7p12.3 are based on analysis including only moderate-to-severe (’Grade B’) endometriosis cases. Risk allele effects of the
remaining three SNPs are from analysis including all endometriosis cases.
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rs77294520 on 2p25.1 also remained signiﬁcant in Grade B
analyses with a larger effect (OR). Results for all SNPs
with Po4.3 10 6 in the GCTA conditional analysis based
on summary statistics including all studies are provided in
Supplementary Data 3. We also performed additional conditional
analysis using European samples alone. Except for near
region-wide signiﬁcance for rs17803970 on 6q25.1 (SYNE1;
P¼ 4.59 10 6) and for rs10757272 on 9p21.3 (CDKN2B-AS1;
P¼ 1.40 10 5), the remaining three secondary association
signals persisted with region-wide signiﬁcance when analysis was
restricted to Europeans studies only (Supplementary Data 4).
Furthermore, there was no linkage disequilibrium (LD) or very
low LD (r2o0.03) between the index SNPs and the ﬁve secondary
association signals on 2p25.1, 6q25.1 and 9p21.3 in both
European and Japanese populations (Supplementary Data 5),
suggesting that the results are not inﬂuenced by differences in LD
patterns across European and Japanese populations. Regional
association and forest plots for the ﬁve secondary signals are
provided in Supplementary Figs 34–42. Taken together, these
data implicate 19 independent SNPs at 14 distinct genomic loci,
including four on 6q25.1—a locus containing a cluster of genes
including ESR1.
On the basis of the ﬁxed-effect GWA meta-analysis results
including all endometriosis cases from European studies, the nine
previously reported SNPs explain 0.97% of the phenotypic
variance on the liability scale19. The 10 new SNPs identiﬁed in
this study together explain a further 0.78%, totalling to 1.75% of
the phenotypic variance explained for endometriosis. More
importantly, the 19 independent SNPs together explained 5.19%
of the phenotypic variance in Grade B endometriosis cases, of
which 2.46% was explained by the 10 new SNPs.
SNP effects based on ancestry and endometriosis deﬁnition.
Of the 14 distinct loci, 6 (2p14, 2q35, 4q12, 6q25.1 (SYNE1),
7p15.2 and 12q22) showed evidence of between-study hetero-
geneity (Pheto0.05; I2: 13.30–20.33) in ﬁxed-effect meta-analysis
including all endometriosis cases; however, after appropriately
modelling the observed heterogeneity in the RE2 model, these
associations remained genome-wide signiﬁcant (Supplementary
Data 2).
None of the six loci showed between-study heterogeneity
in analyses restricted to Japanese alone and self-reported
endometriosis cases (Supplementary Data 6). In Europeans,
ﬁve loci (2p14, 2q35, 4q12, 6q25.1 (SYNE1) and 7p15.2) showed
heterogeneity in allelic associations, and except for 6q25.1
(SYNE1), this trend persisted in surgically conﬁrmed endome-
triosis cases. However, except for 2p14 and 4q12, this hetero-
geneity attenuated in moderate-to-severe endometriosis cases
(Supplementary Data 2). All ﬁve loci except 2p14 produced larger
effect sizes for surgically conﬁrmed endometriosis than diagnosis
based on self-reports. With respect to 2p14, residual between-
study heterogeneity may be driven by opposite direction of effect
in two out of the eight European studies (Supplementary Data 2
and Supplementary Fig. 26).
Most SNPs showed larger effect sizes in Japanese
populations in comparison with results from Europeans alone
(Supplementary Data 6). Whereas all 19 SNPs showed signiﬁcant
associations with endometriosis (Po2.6 10 3 after multiple
testing) in Europeans, only six SNPs showed signiﬁcance in
Japanese alone, although importantly, direction of effects for all
SNPs were concordant with those produced in the meta-analysis.
For surgically conﬁrmed endometriosis, all but two SNPs
(rs2206949 on 6q25.1 and rs10757272 on 9p21.3) showed
signiﬁcant association with endometriosis (Po2.6 10 3 after
multiple testing).
Endometriosis risk SNPs associated with other traits. We
checked genome-wide signiﬁcant associations of the 19 SNPs with
other diseases or traits using the NHGRI GWAS catalogue20. We
searched for 395 SNPs including the 19 SNPs as well as all other
SNPs in high LD (r240.7) with the 19 SNPs (Supplementary
Data 7). Of these, we observed associations with multiple diseases
or traits, including epithelial ovarian cancer21, low-density
lipoprotein cholesterol22, coronary heart disease23, luteinizing
hormone and follicle-stimulating hormone levels, and age at
onset for menopause24.
We did not observe statistically signiﬁcant genetic correlation
between endometriosis and 199 common complex traits, based
on LD score regression analysis25 using LD hub26. Genetic
correlations with nominal Po0.05 are provided in Supplementary
Figs 43,44.
Considering that SNPs at 6q25.1 are reported to be associated
with breast cancer and related phenotypes, we investigated for
overlap of association signals between breast cancer and
endometriosis. A recent study based on the custom-designed
iCOGS data in 118,816 women reported evidence for at least 5
independent risk variants at 6q25.1, each associated with different
breast cancer phenotypes, including oestrogen receptor, human
ERBB2 tumour subtypes, mammographic density, and tumour
grade27. We found no overlap (LD r2o0.17) between these ﬁve
breast cancer signals and our four independent SNPs at the
6q25.1 (ESR1) locus. We therefore obtained association summary
results of 101 SNPs with genome-wide signiﬁcance for overall
breast cancer from Dunning et al.27, and cross-checked with our
GWA meta-analysis results (Supplementary Data 9). Of these,
23 SNPs also showed associations (Po0.05) with endometriosis.
The risk allele of six SNPs was the same for both breast cancer
and endometriosis, including four SNPs (rs851981, rs851980,
rs2206948 and rs150182883) that are in strong LD (r2Z0.60)
with our secondary association signal rs2206949 at 6q25.1 (ESR1).
The secondary endometriosis risk SNP rs2206949 was also
strongly associated with overall breast cancer (P¼ 5.5 10 6).
Based on the 1000 Genomes Project European reference data, the
101 and 23 SNP-sets correspond to four and two independent
SNPs, respectively, thereby suggesting signiﬁcant genetic overlap
between overall breast cancer and endometriosis (P¼ 0.02;
binomial test) at the 6q25.1 (ESR1) locus.
Genes associated with endometriosis. A genome-wide
gene-based test using VEGAS2 (ref. 28) identiﬁed 18 genes
that reached our conservative gene-based threshold of
Po2.23 10 6 (Supplementary Data 10); we also provide
results for all genes with combined Po0.05 for reference. Of
these, 12 genes are located at six GWA SNP risk loci including
1p36.12 (WNT4, LINC00339, LOC101928043 and CDC42),
2p25.1 (GREB1), 2q13 (IL1A and CKAP2L), 7p15.2 (RNU6-16P),
9p21.3 (CDKN2A) and 12q22 (MIR331, MIR3685 and VEZT).
Notably, the remaining six gene-based genome-wide signiﬁcant
association signals were at three novel genomic regions 1q24.3
(DNM3OS, MIR214 and MIR3120), 9q22.32 (MIR23B, MIR27B)
and 16p13.3 (LINC00921).
Fine-mapping of endometriosis risk loci. To identify potential
causal variants responsible for the 19 independent association
signals, we performed ﬁne-mapping analysis based on our GWA
meta-analysis results including all studies except for the Adachi-6
data set, as well as using results from only Europeans.
(Supplementary Data 11). We assumed a single causal variant for
each association signal and constructed a 99% credible set of
variants including SNPs within 500 kb of the index SNP. Except
for the 6q25.1 (SYNE1) locus, the length of the 99% credible
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interval and the number of credible SNPs for all association
signals were smaller in analysis including all studies compared to
the results restricted to only Europeans. Based on results from
all studies, the smallest 99% credible interval was B16.52 kb
observed for rs11674184 on 2p25.1 and the largest was
B604.80 kb for the 6q25.1 (SYNE1). The 99% credible sets for the
19 independent associations using GWA meta-analysis results
including all studies and only Europeans are provided in
Supplementary Data 12.
Bioinformatic analyses of endometriosis risk loci. We then
examined the cis associations between the 19 independent SNPs
and other SNPs in high LD (r240.7) with the lead SNPs
(Supplementary Data 7), and expression of nearby genes in whole
blood, breast, cervix, muscle, ovary, uterus and adipose tissues
using the GTEx eQTL portal29. Of these, the most relevant tissue
for endometriosis is a small set of 32 uterine samples which are a
mixture of both endometrium and myometrium. We found
strong signiﬁcant associations (false discovery rate (FDR)o0.05)
between a SNP and expression of nearby genes in subcutaneous
adipose tissues (Supplementary Data 13). Risk allele (G) of
rs56376645 on 7p15.2 which is associated with endometriosis at
genome-wide signiﬁcance (OR (95% CI)¼ 1.09 (1.06–1.12);
Pall¼ 1.93 10 8) also showed strong associations (beta¼ 0.38;
P¼ 1.44 10 7; FDR¼ 1.28 10 3) with increased expression
of AC003090.1 (Supplementary Fig. 45).
To identify potentially causal genes underlying the identiﬁed
endometriosis associations, we used a novel method30, summary
data-based Mendelian randomization (SMR), which exploits the
concept of Mendelian Randomisation (MR), to test for the
causative effect of an exposure (that is, gene expression) on a
phenotypic outcome (that is, endometriosis) using a genetic
(SNP) variant as an instrumental variable. We used the method to
identify causal genes at our endometriosis risk loci, using the
GWA meta-analysis summary results from all studies including
all endometriosis cases, and the eQTL summary data from
Westra et al.31, an eQTL meta-analysis of 5,311 samples from
peripheral blood, with SNPs imputed to the HapMap2 reference
panel. The SMR analysis identiﬁed two potential causal genes,
CDC42 (rs2268177; PSMR¼ 1.07 10 12) and VEZT (rs14121;
PSMR¼ 3.41 10 6), underlying endometriosis loci at 1p36.12
and 12q22, respectively (Supplementary Data 14). For rs2268177,
there was no signiﬁcant evidence of heterogeneity
(PHEIDI¼ 0.065) in effect sizes of dependent SNPs at this
associated region and therefore it is very likely that rs2268177
contributes to both endometriosis risk and the expression level of
CDC42. Signiﬁcant heterogeneity (PHEIDIo0.05) may indicate the
possibility of two causal variants at a locus: one affecting
endometriosis risk and the other affecting expression level of
the gene (Supplementary Data 15). Signiﬁcant heterogeneity
(PHEIDI¼ 0.004) for rs14,121 was observed, suggesting that
the observed causal effect of VEZT expression on risk of
endometriosis may be due to colocalization, but this needs to
be investigated further.
DEPICT32 analysis provided little support for potential genes,
pathways, tissues or cell types reaching multiple testing threshold
(FDRr0.05). However, when using results with evidence of
genome-wide suggestive association (Po1 10 5) in either
all or Grade B meta-analysis, DEPICT provided evidence for
signiﬁcant enrichment (FDRr0.05) of COPB1 PPI subnetwork
gene set (Supplementary Data 16). Additionally, suggestive
evidence for enrichment (FDRr0.2) was observed for ten
tissues, including female genitalia, uterus, endocrine glands,
endometrium, ovary and Fallopian tubes (Supplementary
Data 16).
Discussion
We conducted a GWA meta-analysis of B7 million SNPs in
17,045 endometriosis cases and 191,596 controls, conﬁrmed 9 out
of 11 previously reported European risk loci, and identiﬁed ﬁve
new genomic regions in or near CCDC170, SYNE1, FSHB, FN1
and 7p12.3 harbouring endometriosis risk loci. This study
represents a nearly ﬁvefold increase in sample size in comparison
with the previously largest endometriosis discovery GWA study
and provided evidence for ﬁve secondary association signals
including ESR1. The variance explained by the ten newly
identiﬁed SNPs in all and Grade B cases was 0.78% and 2.46%,
bringing the total variance explained for endometriosis to 1.75%
and 5.19%, respectively, when considering all 19 associated SNPs.
Importantly, our results highlight key genes involved in
hormone metabolism that are likely to play a major role
in endometriosis pathogenesis, thereby advancing current
knowledge of endometriosis biology.
Previous GWA studies of endometriosis have implicated WNT
signalling, oestrogen responsive genes and genes involved in the
actin cytoskeleton and cellular adhesion12,33. Target genes in
most regions are yet to be identiﬁed, but there is evidence to
support candidates in several regions as previously described34.
The most strongly associated (index) SNP for endometriosis at
the WNT4 locus on chromosome 1p36.12 is also the index SNP
for ovarian cancer35 and the risk mechanism likely acts through
inverse regulation of CDC42 and LINC00339 (ref. 36). The index
SNP associated with endometriosis on chromosome 2p25.1 is a
common splice variant in the oestrogen-responsive growth
Table 2 | Secondary association signals based on summary statistics including all studies and the combined QIMRHCS and
1000G JPTsamples to calculate LD and corresponding results using summary statistics from Grade B analysis and QIMRHCS for
LD estimation.
Chr SNP Position
(bp)
RA OA RAFEUR RAFJPT Endometriosis
cases
RAF OR (95% CI) P value Freq_ref ORcond
(95% CI)
Pcond Associated gene/
cytoband
2 rs77294520 11660955 C G 0.147 — All 0.147 1.16 (1.11–1.21) 9.91 10 13 0.144 1.13 (1.09–1.18) 1.67 10 9 GREB1/2p25.1
Grade B 0.150 1.29 (1.18–1.42) 1.45 10 8 0.147 1.26 (1.15–1.37) 4.76 10 7
6 rs2206949 152037556 T C 0.270 0.162 All 0.262 1.10 (1.06–1.14) 2.73 10 7 0.284 1.11 (1.07–1.15) 2.68 10 8 ESR1/6q25.1
Grade B 0.275 1.09 (1.01–1.17) 2.49 10 2 0.286 1.11 (1.03–1.19) 5.19 10 3
6 rs17803970 152553718 A T 0.918 0.970 All 0.920 1.15 (1.09–1.21) 7.04 10 8 0.919 1.13 (1.07–1.18) 3.25 10 6 SYNE1/6q25.1
Grade B 0.921 1.35 (1.18–1.53) 4.75 10 6 0.918 1.27 (1.12–1.44) 2.21 104
9 rs10757272 22088260 C T 0.521 0.383 All 0.504 1.07 (1.04–1.10) 2.60 10 7 0.506 1.07 (1.04–1.10) 6.35 10 7 CDKN2B-AS1/
9p21.3Grade B 0.524 1.09 (1.02–1.16) 1.12 10 2 0.511 1.08 (1.01–1.15) 1.71 10 2
9 rs1448792 22641633 G A 0.757 0.661 All 0.741 1.08 (1.05–1.12) 1.79 10 7 0.751 1.08 (1.05–1.11) 7.03 10 7 9p21.3
Grade B 0.759 1.06 (0.98–1.14) 1.21 10 1 0.753 1.05 (0.97–1.13) 1.99 10 1
Chr, Chromosome; SNP, single-nucleotide polymorphism; Genomic position is shown related to GRCh37 (hg19); Freq_ref, frequency of the risk allele in the reference sample; LD, linkage disequilibrium;
RA, risk allele; OA, other allele; RAF, OR (95% CI) and P, risk allele frequency, odds ratio and 95% conﬁdence interval, and P value from the meta-analysis; ORcond (95% CI) and Pcond, odds ratio and 95%
conﬁdence interval, and P value from conditional analyses; RAFEUR, risk allele frequency in Europeans; RAFJPT, risk allele frequency in Japanese;.
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regulation by oestrogen in breast cancer 1 (GREB1) gene33,37 and
SNPs associated with endometriosis on chromosome 12q22
increase expression of the transmembrane adherens junctions
protein coding gene vezatin (VEZT) in RNA from blood and
endometrium38. We conﬁrm association near the kinase insert
domain receptor (KDR) gene that was recently reported by the
Icelandic GWA study9. The gene encodes vascular endothelial
growth factor receptor 2, which promotes proliferation,
survival, migration and differentiation of endothelial cells.
KDR is responsive to steroid hormones; expression of KDR
in endometrial stromal cells isolated from proliferative
phase endometrium was signiﬁcantly increased by oestrogen
and medroxyprogesterone acetate in vitro39. During the
premenstrual phase in both humans and macaques, KDR
expression was signiﬁcantly increased in the stromal cells of the
endometrium40. Results from this meta-analysis support and
extend these observations, but further functional studies are
needed to identify and conﬁrm the causal genes in all regions.
We identiﬁed several independent signals in a region that
includes ESR1 encoding oestrogen receptor 1 on chromosome
6p25.1. Endometriosis is an oestrogen-dependent disease. Symp-
toms occur after puberty and oestrogen action contributes to
pathological processes including growth of lesions and inﬂamma-
tion, and to the symptoms including pain41,42. Our primary
meta-analysis identiﬁed two SNPs at this locus—rs1971256 in
CCDC170 and rs71575922 in SYNE1—located up and
downstream of ESR1, respectively. Conditional analysis
identiﬁed a further two independent associations at this locus,
including rs2206949 in ESR1 and rs17803970 in SYNE1. The
6q25.1 region is a well-established susceptibility locus for breast
cancer in both Europeans and Asians27,43,44. Variants at this
locus have recently been associated with overall breast cancer and
its sub-phenotypes including tumour subtypes, mammographic
density and tumour grade27. Of the four independent
endometriosis SNPs at this locus, the association signal for
rs2206949 in intron 2 of ESR1 overlaps with the signal observed
for overall breast cancer. In fact, we observed a signiﬁcant
(P¼ 0.02; binomial test) genetic overlap (sharing) between
genetic risk for overall breast cancer and endometriosis at this
locus, highlighting the importance of hormonal inﬂuences of both
diseases which warrants further detailed exploration.
Our results support a role for a functional effect associated with
endometriosis on chromosome 11p14.1. The association signal
includes an LD region beginning upstream of FSHB and
extending across to ARL14EP. The strongest signal was for SNP
rs74485684 (risk allele T, RAF¼ 0.84, OR¼ 1.11) located
10,276 bp upstream of the transcription start site of FSHB.
Nominal evidence for association between endometriosis and
SNPs upstream of FSHB was recently reported in independent
samples from the UK Biobank providing strong support for
this result45. FSHB encodes the beta polypeptide of FSH,
a glycoprotein hormone that plays a central role in ovarian
folliculogenesis46. Our index SNP rs74485684 is in high LD with
other SNPs located in this region upstream of FSHB including
rs11031005 (r2¼ 0.82) associated with FSH concentrations and
rs11031002 (r2¼ 0.64) associated with LH concentrations24. FSH
and LH are related gonadotropin hormones sharing a common
alpha subunit. The LH beta subunit is located on chromosome
19q13.32 and association between these SNPs on chromosome 11
with concentrations for both hormones suggests a common
mechanism of regulation. They both play central roles in
regulating follicle development in the ovary, inﬂuencing
oestradiol release during the proliferative phase of the cycle46
and contributing to a role for estradiol in endometriosis risk. The
allele(s) associated with increased risk of endometriosis are also
associated with shorter menstrual cycles, earlier age at
menopause, increased dizygotic twinning and polycystic ovarian
syndrome24,45,47,48.
Our results provide further support for association at the
2p25.1 locus, containing an oestrogen-regulated gene, GREB1,
that was ﬁrst identiﬁed in breast cancer cell lines and tumours49.
In addition to conﬁrming the previously identiﬁed association
signal at this locus, our results provide evidence for secondary
association with risk of endometriosis. Regulation of GREB1
transcription by oestrogen receptor a (ERa) is mediated through
three oestrogen response elements (EREs) located 20 kb upstream
of the gene50,51. Moreover, GREB1 functions as an essential
component of the oestrogen receptor transcription complex52,
and while effects of individual risk SNPs are small, the results
suggest that risk variants acting on several genes in the same
pathway act to increase sensitivity to oestrogen and increase the
risk of endometriosis.
This study robustly associated the FN1 locus with
endometriosis, in particular with moderate-to-severe disease.
Association between rs1250248, which is in very high LD
(r2¼ 0.95) with our lead SNP rs1250241 at this locus, was ﬁrst
reported by the earlier European GWA study led by us, but was
not replicated in an independent sample7. Results from the
current study provide genome-wide evidence for the FN1 locus in
Grade B endometriosis, thereby highlighting the importance
of subgroup analysis and phenotype deﬁnition. FN1 encodes
ﬁbronectin, which is a glycoprotein of the extracellular matrix
and is also present in plasma, and at the cell surface. Fibronectin
is involved in important cellular activities including cell adhesion,
growth and migration, and it also plays a critical role in would
healing, blood coagulation and metastasis53.
Our results provide strong evidence for multiple association
signals on chromosome 9p21.3 containing ANRIL (antisense
non-coding RNA in the INK4 locus, also known as CDKN2B-
AS1). A recent Japanese study54 showed allele speciﬁc effects of
rs17761446 on regulation of ANRIL expression with twofold
greater chromatin interactions for the protective G allele with
the ANRIL promoter. SNP rs17761446 is monomorphic in
Europeans and is also in weak LD (r2o0.16) in Japanese with the
SNPs implicated in the current study, suggesting that these
associations are independent endometriosis-speciﬁc risk loci.
SNPs at the chromosome 9p21 locus are also associated with a
number of other diseases, including coronary artery disease
(CAD)—a disease in which ANRIL has previously been
implicated55. Chromatin conformation capture in this region
in human vascular endothelial cells identiﬁed short-range
interactions between sequences at the 9p21.3 locus and
sequences in the vicinity of the genes encoding CDKN2A,
CDKN2B, and MTAP, and long-range interactions with IFNW1
and IFNA21 approximately one million base pairs upstream on
chromosome 9 (ref. 56). Functional studies in mammalian
cells show that ANRIL overexpression accelerated proliferation,
increased adhesion and decreased apoptosis54,56. These functions
may be important in endometriosis and hence, additional studies
will be necessary to understand how SNPs at this locus in both
Japanese and European populations inﬂuence endometriosis.
The majority of the identiﬁed SNP loci showed larger effects in
the Grade B analysis in comparison with those based on analysis
of all endometriosis, supporting previous ﬁndings of greater
genetic loading in moderate-to-severe endometriosis7,8,57.
The smaller effect sizes in analyses including all endometriosis
cases may be due to disease misclassiﬁcation in self-reported
endometriosis cases. However, this would only be part of
the explanation. We have previously shown that the genetic
contribution to phenotypes of surgically conﬁrmed endometriosis
or minimal disease is weaker than for severe disease
phenotypes7,57. Using polygenic prediction analysis, we also
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showed signiﬁcant prediction of minimal disease between two
independent data sets with surgically conﬁrmed endometriosis57.
In summary, this GWA meta-analysis of endometriosis
provides evidence for 10 new independent SNP loci, and more
than doubles the proportion of genetic variation in endometriosis
explained by robust SNP risk loci. These results identify novel
variants in or near speciﬁc genes with important roles in sex
steroid hormone signalling and function, and offer unique
opportunities for more targeted functional research efforts.
Methods
Study overview and GWA Genotyping. Our study included 17,045 endometriosis
cases and 191,596 controls from 11 individual case–control data sets of European
and Japanese ancestry. The European ancestry arm included 14,926 cases and
189,715 controls from eight individual case–control data sets and the Japanese data
sets included 2,119 cases and 2,143 controls from three cohorts. The samples were
genotyped on a variety of commercial arrays, as outlined in the Supplementary
Information. All samples were collected with informed consent and study protocols
were approved by the relevant local institutional ethics committees: the QIMR
Human Research Ethics Committee (QIMR), the University of Newcastle and
Hunter New England Population Health Human Research Ethics Committees
(HCS), the Oxford regional multi-center and local Research Ethics Committees
(UK), the Ethical Committees at the Institute of Medical Science at the University
of Tokyo and the Center for Genomic Medicine at the RIKEN Yokohama Institute
(BBJ), the Commission of Medical Ethics of the Leuven University Hospital
(LEUVEN), the Human Subject Committee of Harvard School of Public Health
and the Institutional Review Board of Brigham and Women’s Hospital (NHS2 and
WGHS), the Ethical Committee of the University of Niigata and the afﬁliated
hospitals (Adachi), the Ethical and Independent Review Services (http://
www.eandireview.com) (23andMe), the Danish Research Ethical Committee
System (iPSYCH), and the Data Protection Commission of Iceland and the
National Bioethics Committee of Iceland (deCODE).
Genome-wide imputation. Genotype data within each case–control data set were
subjected to sample and SNP quality control as described in the Supplementary
Information. Following a shared protocol, each GWA case–control data set was
imputed separately. Imputation was carried out using either minimac58,59
(QIMRHCS, LEUVEN, OX, 23andMe, NHS2-dbGaP, BBJ, WGHS and
Adachi-500 k), IMPUTE2 (ref. 60) (iPSYCH) or in-house methods9 (deCODE).
For QIMRHCS, LEUVEN, OX, NHS2-dbGaP, BBJ, WGHS, Adachi-500K and
iPSYCH samples, 1000 Genomes Project March 2012 haplotypes were used as the
reference panel, whereas for 23andMe and deCODE samples, 1000 Genomes
Project October 2010 haplotypes and whole genome sequence data (B30 million
sequence variants) of 8,453 Icelanders were used as the reference for imputation,
respectively. For the Adachi-6 data set, individual-level genotype data for all
samples were not available and hence no imputation was performed.
Genome-wide association analysis. Imputed genotypes with low imputation
quality (o0.3 for minimac ando0.4 for IMPUTE2) in each data set were excluded
from the downstream analysis. Association analysis of the imputed (dosage scores
or best guess genotypes) or observed genotypes in each case-control data set
including all endometriosis cases (‘All’) was performed using PLINK61,
SNPTEST62 or ProbABEL63, assuming an additive model of genetic inheritance.
Imputed genotypes in the 23andMe data set were analysed by adjusting for age
and the top ﬁve principal components, whereas QIMRHCS, LEUVEN, OX,
NHS2-dbGaP, BBJ and Adachi-500 K data sets were analysed without any
covariates. For Adachi-6 data set, association analysis was performed using the
directly measured genotypes without any covariates. Association analysis of
deCODE data was performed using logistic regression9, and included adjustment
for age and population substructures. The iPSYCH were analysed by adjusting for
genotyping waves and the top ﬁve principal components.
Genome-wide meta-analysis. The primary meta-analysis of ‘All’ endometriosis
cases versus controls in the 11 individual case–control data sets was performed
using the inverse variance-weighted ﬁxed-effect model in METAL13. The P value
threshold of 5 10 8 was declared as genome-wide signiﬁcant, and SNPs with
association at Po1 10 5 were considered to show a suggestive association.
Heterogeneity of allelic associations was examined using the Cochran’s Q statistic64
Po0.05, as well as the I2 index65, which indicates the proportion of variance
attributable to between-study heterogeneity. Meta-analysis of SNPs associated in
the ﬁxed-effect model at Po1 10 5 and showing evidence of heterogeneity
(Po0.05) was also carried out using the Han Eskin random-effects model (RE2)17
implemented in METASOFT program. Compared to the conventional random-
effects model, the RE2 model offers greater power under heterogeneity. The RE2
model relaxes the conservative assumption in hypothesis testing in the traditional
RE approach and assumes no heterogeneity under the null hypothesis.
Considering the relatively greater genetic loading (liability) of moderate-to-
severe (Grade B) endometriosis (rAFS stage III or IV disease) compared to minimal
or mild (Grade A) endometriosis (rAFS stage I or II disease or limited ovarian
involvement)7,8,57, a secondary analysis was performed for SNPs associated at
Po0.05, where we performed meta-analysis of Grade B cases versus controls in the
QIMRHCS, deCODE, LEUVEN and OX case–control data sets, where disease stage
information was readily available.
Per-study Q–Q plots of GWA P values are provided in Supplementary
Figs 1–10 as well as the Q–Q plot for GWA meta-analysis P values (Supplementary
Fig. 11). We also provide Q–Q plots for the GWA meta-analysis P values, after
excluding the eight previously identiﬁed risk loci (Supplementary Fig. 12).
Conditional analysis. We used GCTA18 to perform approximate conditional
GWA analysis of the newly identiﬁed and conﬁrmed risk loci for endometriosis.
GCTA allows performing conditional analysis using summary results from GWA
meta-analysis and estimated LD from a sufﬁciently large reference population used
in the meta-analysis. Given that the GWA meta-analysis included individuals of
both European (B98%) and Japanese (B2%) ancestries, we used a reference
population with similar proportion of European and Japanese individuals to
calculate the LD. Best guess genotypes of well-imputed (minimac r240.8) SNPs in
the QIMRHCS 1,000 Genomes imputed data were then subjected to quality control
to exclude SNPs with Hardy-Weinberg Equilibrium Po1 10 6 in controls,
MAFo0.01 and 45% missingness. As recommended by Yang et al.66, samples
with estimated relationship score 40.025 were also excluded (as opposed to 0.2
used in the meta-analysis), leaving to total of 4,695 samples for further analysis. We
then combined the QIMRHCS data set with genotypes of 96 individuals (B2%)
obtained from the 1000 Genomes Japanese reference data, resulting in 4,791
samples with 7,346,981 autosomal SNPs for LD calculation. To examine if the
results were inﬂuenced by cross-ancestry LD patterns, we also performed
additional conditional analysis using summary statistics from European samples
alone and calculated LD from only QIMRHCS samples, and compared the results
with those from using both QIMRHCS and the 1000 Genomes Japanese samples.
For each genomic locus (new or conﬁrmed) with Po5 10 8, we
conservatively searched ±500 kb surrounding the lead SNP to ensure potential
long-range genetic inﬂuences were assessed, and adjusted GWA summary data for
the lead SNP using the—massoc-cond option in the GCTA18. On the basis of
genotype data of the reference samples, we ﬁrst estimated the effective number of
independent SNPs within each locus using Genetic type 1 error calculator (GEC)67,
and then totalled them across all the loci examined for secondary signals. Based on
the combined QIMRHCS and 1000 Genomes Japanese reference samples, the
effective number of SNPs across all the 14 risk loci was 11,631, and hence we
declared secondary signal if a SNP achieved Po4.3 10 6 (0.05/11,631).
Where an additional SNP reached threshold for secondary signal after
adjustment for the lead SNP, we performed an additional round including both
SNPs. If the remaining SNPs had a P value larger than the threshold for secondary
signal, no further analysis was performed.
Characterization of endometriosis-associated SNP effects. To examine the
effect of potential sources of heterogeneity between groups, we compared effect
estimates of our 19 independent risk SNPs for Europeans versus Japanese.
To address the effects of disease deﬁnition, we also compared the effect estimates
of studies with a surgically conﬁrmed diagnosis of endometriosis with those with
self-reported endometriosis. A Bonferroni-corrected Po2.6 10 3 (corrected
for 19 tests) was used to assess statistical signiﬁcance. Heterogeneity of allelic
associations was examined using the Cochran’s Q statistic64 and evidence of
heterogeneity was declared if Pheto0.05.
Comparison of identiﬁed loci with other traits. We searched the NHGRI GWAS
catalogue20 for SNP-trait associations, in particular reproductive traits, at our risk
loci. SNPs within 500 kb and in LD (r240.7; arbitrary number) with the lead SNP
at each associated locus were identiﬁed using the 1000 Genomes Project pilot 1
genotype data and LD values from CEU population. All the SNPs within each locus
were then searched in the NHGRI catalogue (downloaded on 3 March 2016) for
genome-wide signiﬁcant associations with other traits or diseases. Using LD-hub26,
we also performed LD score regression analysis25 to estimate genetic correlation
between endometriosis and 199 other traits using summary statistics from
ﬁxed-effect meta-analysis including all and Grade B endometriosis cases.
A Bonferroni-corrected Po2.5 10 4 (corrected for 199 tests) was used to assess
statistical signiﬁcance.
Gene-based association analysis. Gene-based approaches can be more powerful
than single SNP analyses, in part due to accounting for allelic heterogeneity
(if present) and LD between SNPs, and restricting to genic regions thereby
reducing the multiple-testing problem of traditional GWA study. Therefore, using
the GWA data from all of the 11 individual case–control data sets, we performed
genome-wide gene-based association analysis using VEGAS2 (ref. 28). We ﬁrst
extracted the 4,699,992 SNPs present in all the GWA data sets except Adachi-6
as it includes only observed SNPs and P values from GWA data sets including
individuals with European ancestry and the P values from the GWA data sets
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including individuals of Japanese ancestry, and analysed separately using VEGAS2.
For each gene, the VEGAS test produces a gene-based P value by incorporating
evidence of association from all SNPs across the gene, while accounting for gene
size and LD between SNPs. The resulting gene-based P values from GWA studies
of European and Japanese ancestry were combined using Stouffer’s Z-score
combined P value method. We tested a total of 22,406 genes (including 10 kb
50 and 30 to their transcriptional start and end positions) with association results
for at least two SNPs, and used a Bonferroni-adjusted signiﬁcance threshold
of Po2.23 10 6 (0.05/22,406) to declare genome-wide signiﬁcance for
gene-based tests.
Fine-mapping analysis. For each independent SNP, we deﬁned a genomic region
500 kb on either side of the index SNP and computed 99% credible intervals likely
to contain the causal variant using a Bayesian approach, with the strength
of evidence for association measured using the Bayes factor for each SNP68,69.
To assess the resolution of ﬁne-mapping offered by meta-analysis including
individuals of both European and Japanese ancestries, we calculated the 99%
credible sets based on GWA meta-analysis results including all studies but
Adachi-6, as well as results based on only European studies. We did not compute
the 99% credible sets for the Japanese alone because the small sample size makes
comparison of ﬁne-mapping intervals meaningless. We calculated approximate
Bayes’ factor (BF) for each SNP using:
BFi ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1Ri
p
exp  Rb2i2s2i
 
where bi is the allelic effect of the ith SNP, with corresponding standard error si,
and Ri¼ 0.04/(si2þ 0.04), which incorporates a N(0,0.22) prior for bi assigning
high probability to small effect sizes and only small probability to large effect sizes.
Adachi-6 data set with only observed SNPs was excluded to maintain uniform SNP
coverage across studies. Using the below formula, we calculated the posterior
probability that the ith SNP is causal:
ji ¼
BFiP
i BFi
where the summation in the denominator is over all the SNPs passing quality
control across the locus. We assumed a single causal variant for each association
signal, calculated BF for all SNPs within 500 kb of the index SNP, and ranked the
SNPs based on their BF. We then constructed a 99% credible set of variants by
combining the ranked SNPs, and calculated the number of SNPs and length of
genomic region covered by each credible set.
Identiﬁcation of putative functional variants. We examined the cis associations
between the 19 independent SNPs and other SNPs in high LD (r240.7) with the
lead SNPs and expression of nearby genes using the GTEx eQTL portal29. A total of
395 SNPs were searched.
We used summary data-based Mendelian randomization (SMR)30 to identify
potentially causal genes underlying the identiﬁed endometriosis associations.
Brieﬂy, the SMR method exploits the concept of MR analysis; it tests for the
causative effect of an exposure on an outcome using a genetic variant (for example,
SNP) as an instrumental variable. In principle, it uses the MR analysis (for example,
two-stage least squares approach) to search for causal genes at the loci identiﬁed
from GWA studies for complex traits. Using summary data from GWA and eQTL
studies, the SMR method tests the association between a trait and the expression
level of each gene across the whole genome. We used the method to identify causal
genes at our endometriosis loci, using the GWA meta-analysis summary results
from all studies including all endometriosis cases, and the eQTL summary data
from Westra et al.31, an eQTL meta-analysis of 5,311 samples from peripheral
blood, with SNPs imputed to the HapMap2 reference panels. Of the 14,329 probes
in the eQTL data, only probes with at least one cis-eQTL at Po5 10 8 were
included while excluding probes in the MHC region, resulting in 5,967 probes for
ﬁnal SMR analysis. Therefore, genes with Po8.4 10 6 (equivalent to 0.05/5,967)
were declared to achieve genome-wide signiﬁcance in the SMR analysis. SMR
method also tests this colocalization using the HEIDI (Heterogeneity In Dependent
Instruments) test. A Po0.05 in the HEIDI test suggests that the majority of the
associations identiﬁed by the SMR test could be explained by colocalization.
Pathway analysis. We used Data-driven Expression-Prioritized Integration for
Complex Traits (DEPICT)32 to identify genes and pathways responsible for the
observed genetic associations, thereby gaining biological insights at the identiﬁed
risk loci. Using comprehensive data on gene expression, molecular pathways,
experimentally derived protein-protein interactions, phenotypic gene sets,
Reactome and KEGG pathways and gene ontology terms, DEPICT highlights the
causal genes at each risk locus, enriched pathways and the relevant tissues/cell
types where associated genes are highly expressed. Based on the results from the
ﬁxed-effect meta-analysis of all the GWA data set, we ran DEPICT analyses on
(i) SNPs showing genome-wide signiﬁcant (Po5 10 8) association, and
(ii) SNPs with suggestive (Po1 10 5) association signal in GWA meta-analysis
including all or Grade B cases.
Variance explained. Based on Neil Risch’s liability threshold model19, we
estimated proportion of variance explained by a single SNP using the effect allele
frequency and odds ratio from the GWA meta-analysis of European studies.
We used population prevalence of 8 (refs 7,70) and 2.5% (ref. 71) for all and Grade
B endometriosis cases, respectively.
Assuming associated SNPs are not in high LD, we calculated the sum of
single-SNP explained variances to produce the total variance explained by a set of
independent SNPs72.
Data availability. The authors declare that the data supporting the ﬁndings of this
study are available within the article and its Supplementary Information Files.
For additional data (beyond those included in the main text and Supplementary
Information) that support the ﬁndings of this study, please contact the corre-
sponding authors.
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